BPC-157 und TB-500 als Paar, an der Literatur gelesen
Die Kombination aus BPC-157 und TB-500, oft als Regenerationsstack vermarktet, an der Evidenz: was jede Substanz im Tiermodell tut, warum keine Humanstudie das Paar getestet hat und worauf die Begeisterung beruht.
By The PepVise Editorial Team · Reviewed August 6, 2026 · 9 min read
Side-by-side comparisons on PepVise rank by weight of evidence, not by bodybuilding forum consensus. Tier badges on every entry.
How we read the literature
- Evidence tier
- We grade the literature on four tiers, High (replicated RCTs or meta-analyses), Moderate (multiple trials with mixed findings), Low (a single pilot or case series), and Anecdotal (preclinical only, no human data). The tier appears on every compound profile beside the claim it supports.
- Trial stage
- Where a compound sits in the human development pipeline is recorded as Preclinical, Phase 1, Phase 2, or Phase 3+. We pull the current stage from ClinicalTrials.gov and the EU Clinical Trials Register on access date and re-verify quarterly.
- Regulatory status
- We state the FDA posture plainly, approved for indication X, or labeled for research use only, or removed from the 503A list, or investigational under a specific IND. Regulatory status changes; every post carries a review date.
- Where we're uncertain
- Every compound profile closes with a named uncertainty section, the question we can't answer from the current literature, the trial we'd want to see, the effect size we'd treat as a real signal. Uncertainty is not a failure mode here; it's load-bearing.
What readers ask us next.
- Ist das Stacken von BPC-157 und TB-500 nachweislich wirksam?
- Nein. Es gibt keine kontrollierte Humanstudie der beiden Substanzen zusammen und keine veröffentlichte präklinische Studie der konkreten Kombination. Jede hat eigene Tierdaten, überwiegend an Ratten, aber das Kombinieren zweier einzeln nicht zugelassener Substanzen erzeugt keine Evidenz für das Paar. Der Stack ist eine Hypothese, keine belegte Therapie.
- Sind BPC-157 und TB-500 von der FDA zugelassen?
- Keine der beiden ist in den USA ein für den menschlichen Gebrauch zugelassenes Arzneimittel, und beide werden meist nur zu Forschungszwecken deklariert verkauft. 2023 ordnete die FDA BPC-157 in eine Kategorie ein, die es unter den einschlägigen Bestimmungen faktisch vom Compounding ausschließt. Dieser regulatorische Status ist von jeder Wirksamkeitsbehauptung getrennt.
- Was unterscheidet TB-500 von Thymosin beta-4?
- Der Großteil der regenerativen Forschung beschreibt das vollständige Thymosin beta-4, das natürliche Peptid aus 43 Aminosäuren. TB-500 wird als verwandtes Fragment vermarktet, und beide werden in Verkaufstexten oft als austauschbar behandelt, doch die veröffentlichten Daten zu Wundheilung und Herzreparatur nutzten weitgehend das vollständige Molekül, sodass die Übertragung auf das Fragment eine Annahme ist.
- Ist die Kombination sicher?
- Ihre Sicherheit am Menschen ist nicht belegt. Langzeit-Humandaten fehlen für beide Substanzen einzeln, erst recht zusammen, und Material in Forschungsqualität birgt Reinheits- und Kontaminationsrisiken. Das Ausbleiben berichteter Schäden in Foren ist nicht dasselbe wie nachgewiesene Sicherheit.
A new Phase 2 trial for any of the ranked compounds. A regulatory action changing FDA status. A published replication failure in an independent lab. Any of those would move entries on this list within a week, with a dated note on what changed.
References cited on this page.
PubMed, ClinicalTrials.gov, and FDA documents only. Secondary sources appear when needed to characterize public discourse, never as a source for a clinical claim.
- [01]Staresinic M et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon. J Orthop Res 2003;21:976-983
- [02]Krivic A et al. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing. J Orthop Res 2006;24:982-989
- [03]Malinda KM et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol 1999
- [04]Goldstein AL et al. Thymosin beta4: a multi-functional regenerative peptide. Expert Opin Biol Ther 2012
- [05]Sikiric P et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des 2011
About The Pepvise Editorial Team
The Pepvise Editorial Team is a small group of researchers and science writers reading the peer-reviewed peptide literature and translating it into calm, cited analysis. We do not sell peptides, recommend peptides, or tell readers what to administer. We describe what has been measured, by whom, at what scale, with what effect size.
Compound reviews are signed off by Dr. Priya Narang, MD, MPH (endocrinologist) and Dr. Marcus Haley, PharmD, BCPS (board-certified clinical pharmacist). Both hold verifiable state-board licenses and have signed editorial-independence letters with us. See the full editorial board →
Adjacent in the literature.
GHK-Cu Topical vs Injection: Where the Evidence Sits
GHK-Cu topical versus injection on the evidence: why nearly all the human-relevant data is topical, why injectable use has no trial and raises copper-safety questions, and how to read the two routes honestly.
8 min readEvidence · ExplainerGHK-Cu Before and After: What to Expect From the Evidence
GHK-Cu before-and-after on the evidence: what the skin and hair studies actually measured, why online transformation photos are not trial data, and a realistic view of the timeframes and magnitudes involved.
7 min readEvidence · ExplainerPeptides for Healing: What the Evidence Actually Supports
Peptides for healing on the evidence: which repair-associated peptides have human data, which rest on animal wound-healing models, and why the strongest healing peptide is one most people already know.
9 min readGet the 2026 Peptide Evidence Ledger.
A 12-page PDF summary of where 10 major compounds sit, Preclinical / Human pilot / Phase trial / FDA status. Updated quarterly. Free.
By subscribing, you agree to our Privacy Policy. One calm, cited email a week. Unsubscribe anytime.